New perspectives on metabolic imaging in the management of prostate cancer in 2022: A focus on radiolabeled PSMA‑PET/CT (Review)
Résumé
Nuclear medicine is an essential part of prostate cancer management concerning initial staging, patient’s follow-up and even therapy. PSMA is a glutamate carboxypeptidase II transmembrane glycoprotein expressed by 80% of prostatic cells. Its interest resides in its specificity for prostatic tissue. The use of 68GaPSMA PET/CT in the context of disease staging is thus well-established and recommended, especially for high-risk disease with metastases and lymph node involvement. However, the risk of false positives raises questions about its place in the management of patients with prostate cancer.
The purpose of this article is to recall the place of PET-PSMA in the care of patients with prostate cancer but also its limits of use.